AU2023228045A1 - Combinations of ctps1 and bcl2 inhibitors for cancer - Google Patents

Combinations of ctps1 and bcl2 inhibitors for cancer Download PDF

Info

Publication number
AU2023228045A1
AU2023228045A1 AU2023228045A AU2023228045A AU2023228045A1 AU 2023228045 A1 AU2023228045 A1 AU 2023228045A1 AU 2023228045 A AU2023228045 A AU 2023228045A AU 2023228045 A AU2023228045 A AU 2023228045A AU 2023228045 A1 AU2023228045 A1 AU 2023228045A1
Authority
AU
Australia
Prior art keywords
inhibitor
cyclopropanesulfonamido
ctps1
thiazol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023228045A
Other languages
English (en)
Inventor
Philip BEER
David Chiron
Andrew Parker
Catherine Pellat-Deceunynck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Step Pharma SAS
Original Assignee
Step Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Step Pharma SAS filed Critical Step Pharma SAS
Publication of AU2023228045A1 publication Critical patent/AU2023228045A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023228045A 2022-03-01 2023-03-01 Combinations of ctps1 and bcl2 inhibitors for cancer Pending AU2023228045A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22305225.9 2022-03-01
EP22305225 2022-03-01
EP22306429.6 2022-09-27
EP22306429 2022-09-27
PCT/EP2023/055217 WO2023166076A1 (en) 2022-03-01 2023-03-01 Combinations of ctps1 and bcl2 inhibitors for cancer

Publications (1)

Publication Number Publication Date
AU2023228045A1 true AU2023228045A1 (en) 2024-08-15

Family

ID=85384465

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023228045A Pending AU2023228045A1 (en) 2022-03-01 2023-03-01 Combinations of ctps1 and bcl2 inhibitors for cancer

Country Status (6)

Country Link
US (1) US20250177394A1 (https=)
EP (1) EP4486347A1 (https=)
JP (1) JP2025508896A (https=)
AU (1) AU2023228045A1 (https=)
CA (1) CA3244038A1 (https=)
WO (1) WO2023166076A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
IL288508B2 (en) 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
WO2024133730A1 (en) * 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3717465B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
WO2019106156A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
MX2020009887A (es) 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
IL288508B2 (en) 2019-06-04 2026-02-01 Step Pharma S A S History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human CTPS1 inhibitors for the treatment of proliferative diseases
EP3980410B1 (en) 2019-06-04 2025-02-19 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl)butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
EP4041715A1 (en) 2019-09-20 2022-08-17 Step Pharma S.A.S. Sulfonamide inhibitors as ctps 1 inhibitors
WO2021053402A2 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Compounds
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof

Also Published As

Publication number Publication date
EP4486347A1 (en) 2025-01-08
CA3244038A1 (en) 2023-09-07
US20250177394A1 (en) 2025-06-05
JP2025508896A (ja) 2025-04-10
WO2023166076A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
US20250177394A1 (en) Combinations of ctps1 and bcl2 inhibitors for cancer
WO2023166078A1 (en) Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
CN113980014B (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI651303B (zh) 經取代苯化合物
US9173893B2 (en) Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
JP7595593B2 (ja) 増殖性疾患の治療のための、ヒトｃｔｐｓ１阻害剤としてのｎ－（５－（６－エトキシピラジン－２－イル）ピリジン－２－イル）－４－（２－（メチルスルホンアミド）ピリミジン－４－イル）テトラヒドロ－２ｈ－ピラン－４－カルボキサミド誘導体及び関連化合物
WO2023166077A1 (en) Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
JP5997143B2 (ja) タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン
WO2024133721A1 (en) Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
KR20150093695A (ko) Malt1의 소분자 억제제
PT2331537E (pt) Derivados de 1-((5-heteroariltiazol-2-il)aminocarbonil)pirrolidina-2-carboxamida como inibidores de fosfatidilinositol 3-quinase (pi3k) úteis no tratamento de doenças proliferativas
WO2020245665A1 (en) N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
WO2024133730A1 (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
WO2023166080A1 (en) Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
Petrelli et al. Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade
WO2019219805A1 (en) Combination therapy
JP2018510134A (ja) 組合せがん治療法
JP2023539754A (ja) Ｌｚｋ標的化分解剤および使用方法
CN117916234A (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
JP7005508B2 (ja) ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体
CN118804752A (zh) Ctps1和bcl2抑制剂联合治疗癌症
He Unraveling PI5P4K’s Immunomodulatory Role in Lung Cancer Tumor Microenvironment⎯ A Druggable Target to Promote Anti-Tumor Immunity
CA3087359C (en) Metabolites of bictegravir
Petrelli et al. Novel inhibitors of inosine monophosphate dehydrogenase as potential anti-cancer drugs: A patent review (2002-2014)
WO2026027753A1 (en) Ctps1 inhibitors for the treatment of myeloproliferative neoplasms